The role of incretin-based therapies in the management of type 2 diabetes.

Prabirkumar Bandyopadhyay
{"title":"The role of incretin-based therapies in the management of type 2 diabetes.","authors":"Prabirkumar Bandyopadhyay","doi":"10.1358/dnp.2009.22.9.1434633","DOIUrl":null,"url":null,"abstract":"<p><p>Type 2 diabetes (T2D) is associated with a greatly increased risk of cardiovascular disease. An increasing need for glucose-lowering treatments is emphasized by the almost inevitable failure of monotherapy and occurrence of weight gain. Recently, novel classes of drugs derived from the incretin system have been introduced into the management of T2D. Recent advances in the field of incretin-based therapies in the management of T2D were discussed at the 45th Annual Meeting of the European Association for the Study of Diabetes, held from September 29 until October 2, 2009, in Vienna, Austria.</p>","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"22 9","pages":"559-67"},"PeriodicalIF":0.0000,"publicationDate":"2009-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug news & perspectives","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1358/dnp.2009.22.9.1434633","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Type 2 diabetes (T2D) is associated with a greatly increased risk of cardiovascular disease. An increasing need for glucose-lowering treatments is emphasized by the almost inevitable failure of monotherapy and occurrence of weight gain. Recently, novel classes of drugs derived from the incretin system have been introduced into the management of T2D. Recent advances in the field of incretin-based therapies in the management of T2D were discussed at the 45th Annual Meeting of the European Association for the Study of Diabetes, held from September 29 until October 2, 2009, in Vienna, Austria.

以肠促胰岛素为基础的治疗在2型糖尿病治疗中的作用。
2型糖尿病(T2D)与心血管疾病的风险大大增加有关。单药治疗几乎不可避免的失败和体重增加的发生强调了对降糖治疗的日益增长的需求。最近,从肠促胰岛素系统衍生的新型药物被引入到T2D的治疗中。2009年9月29日至10月2日在奥地利维也纳举行的第45届欧洲糖尿病研究协会年会上讨论了以肠促胰岛素为基础的T2D治疗领域的最新进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drug news & perspectives
Drug news & perspectives 医学-药学
自引率
0.00%
发文量
0
审稿时长
>12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信